Nicholas Puro

China Opportunity Acquisition Corp. is a blank check company formed for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition or other similar business combination. The company was founded on August 7, 2006 and is headquartered in New York, NY.

Edelson Technology Partners (Edelson Technology Partners) is a venture capital firm founded in 1984 by Harry Edelson. The firm is headquartered in Montvale, New Jersey.

National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC.

Temptime Corp. manufactures and distributes temperature monitoring devices. It offers scientifically based, time-temperature indicators that alert patients, doctors, and other healthcare professionals. The company was founded by Thaddeus Prusik in 1987 and is headquartered in Morris Plains, NJ.

Pavia & Harcourt LLP is a business law firm established in 1951, specializing in commercial, corporate, banking, media and entertainment, real estate, litigation and arbitration, intellectual property, estate planning and administration, and matrimonial & family law. The firm is based in New York, NY and has extensive international experience with attorneys fluent in Italian, French, Spanish, Russian, and Portuguese. Pavia & Harcourt represents foreign entities and individuals who do business in the US as well as American clients who do business both domestically and abroad. The private company offers a full range of legal services to foreign companies, individuals, and governmental organizations and agencies.

MidAtlantic Fund LLC (MidAtlantic Fund) is a venture capital firm founded in 2007 by Richard Johnson. The firm is headquartered in New York.

MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX.